Other Events ·
Nasdaq notifies Oncolytics Biotech of non-compliance with $1.00 minimum bid price requirement
ONCYOncolytics Biotech Inc
On July 20, 2026, Oncolytics Biotech Inc. received notification from Nasdaq that its common stock failed to meet the $1.00 minimum bid price requirement after closing below that level for 30 consecutive business days. The company has a compliance period until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to regain compliance may lead to delisting, although an additional 180-day extension may be available if certain criteria are met. The company is currently assessing options to maintain its listing. This company is a biotechnology firm that develops immunotherapies for the treatment of cancer.